Aspira Women's Health Inc announces that it has entered into a Securities Purchase Agreement to issue 1,368,600 shares of common stock to certain Purchasers at an offering price of $3.50 per share and accompanying warrants to purchase 1,571,000 shares of Common Stock for the aggregate gross proceeds of approximately $5.5 million on January 24, 2024. The transaction will include participation from individual investor such as Sandford for 2,400 shares of common stock at an offering price of $4.255 per share and accompanying Purchase Warrant which was the consolidated closing bid price of our common stock on The Nasdaq Capital Market. The warrants to the institutional investor and certain existing investors will have an exercise price of $4.00 per share and the warrants to the officer of the Company will have an exercise price of $4.13 per share, both warrants to the existing shareholders and the officer of the Company will be exercisable beginning six months after issuance and will expire 5 years from the initial exercise date.

The transaction is expected to close on January 26, 2024. The company will pay the placement agent cash fee equal to 7.0% of the aggregate gross proceeds generated from the transaction except that, with respect to proceeds raised in this Offering from certain designated persons, AGP?s cash fee is reduced to 3.5% of such proceeds,